临床药师参与肺癌患者靶向治疗的药学服务实践

doi:10.3969/j.issn.1000-8535.2024.06.008

广州医药 ›› 2024, Vol. 55 ›› Issue (6): 626-630.DOI: 10.3969/j.issn.1000-8535.2024.06.008

临床药师参与肺癌患者靶向治疗的药学服务实践

殷秋忆, 江艳

南通大学附属常熟医院药学部（江苏常熟 215500）

收稿日期:2023-10-05 出版日期:2024-06-20 发布日期:2024-07-31
通讯作者: 江艳,E-mail：jiangyan_csey@163.com

Clinical pharmacists involved pharmaceutical care practice of targeted therapy for lung cancer patients

YIN Qiuyi, JIANG Yan

Department of Pharmacy,Affiliated Changshu Hospital of Nantong University,Changshu 215500,China

Received:2023-10-05 Online:2024-06-20 Published:2024-07-31

摘要/Abstract

摘要： 本文探讨临床药师对口服靶向药物的非小细胞肺癌患者开展药学服务的要点,以案例为依据,通过查阅药品说明书、指南及文献等,分析药学服务的内容和方向。临床药师在安全性评估、剂量调整、个体化治疗方案选择、用药教育和健康宣教等方面为患者和临床医生提供专业、全面的药学服务。临床药师通过全程参与患者的治疗过程,指导患者正确用药、优化治疗方案,利用专业优势解决临床实际问题,提升药学服务质量的同时体现了药师的职业价值。

关键词: 非小细胞肺癌, 靶向药物, 药学服务, 用药教育

Abstract: To explore the key points of pharmaceutical care for non-small cell lung cancer patients with oral targeted drugs．Based on clinical cases,the content and direction of pharmaceutical care were analyzed with drug instructions,guidelines and literature．Clinical pharmacists provided professional and comprehensive pharmaceutical services for patients and clinicians in safety assessment,dose adjustment,individualized treatment plan selection,medication education and health education．Clinical pharmacists participate in the whole treatment process,guide patients to use drugs correctly,optimize treatment plans,use professional advantages to solve clinical practical problems,improve the quality of pharmaceutical care and reflect the professional value of pharmacists．

Key words: non-small cell lung cancer, targeted drugs, pharmaceutical care, drug education

殷秋忆, 江艳. 临床药师参与肺癌患者靶向治疗的药学服务实践[J]. 广州医药, 2024, 55(6): 626-630.

YIN Qiuyi, JIANG Yan. Clinical pharmacists involved pharmaceutical care practice of targeted therapy for lung cancer patients[J]. Guangzhou Medical Journal, 2024, 55(6): 626-630.

参考文献

[1] 宁丽娜,杜敏娟,李立丰.非小细胞肺癌分子靶向治疗的研究进展[J].中国现代药物应用,2021,15(8):241-243.
[2] ZHAO Y Y,XUE C,JIANG W,et al.Predictive value of intratumoral microvascular density in patients with advanced non-small cell lung cancer receiving chemotherapy plus bevacizumab[J].J Thorac Oncol,2012,7(1):71-75.
[3] LI M,KROETZ D L.Bevacizumab-induced hypertension:Clinical presentation and molecular understanding[J].Pharmacol Ther,2018(182):152-160.
[4] 付裕豪,邱学佳,李宵,等.第三代EGFR-TKIs在晚期非小细胞肺癌中的遴选量化评估[J].中国医院药学杂志,2023,43(1):21-27.
[5] 顾航烨,吕晴,陈永.伏美替尼治疗EGFR基因突变非小细胞肺癌的研究进展[J].中国药房,2023,34(14):1788-1792.
[6] 中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)非小细胞肺癌诊疗指南2022[M].北京:人民卫生出版社,2022:96-97.
[7] CHENG Y,HE Y,LI W,et al.Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC:FLAURA China,A randomized study[J].Target Oncol,2021,16(2):165-176.
[8] LU S,DONG X,JIAN H,et al.AENEAS:A Randomized Phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or MetastaticNon-small-cell lung cancer with EGFR Exon 19 deletion or L858R mutations[J].J Clin Oncol,2022,40(27):3162-3171.
[9] SHI Y,CHEN G,WANG X,et al.Furmonertinib(AST2818)versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer(FURLONG):A multicentre,double-blind,randomised phase 3 study[J].Lancet Respir Med,2022,10(11):1019-1028.
[10] SOLOMON B J,MOK T,KIM D W,et al.First-line crizotinib versus chemotherapy in ALK-positive lung cancer[J].N Engl J Med,2014,371(23):2167-2177.
[11] 王可,李娟,孙建国,等.间变性淋巴瘤激酶抑制剂不良反应管理西南专家建议(2021年版)[J].中国肺癌杂志,2021,24(12):815-828.
[12] CAPPUZZO F,MORO-SIBILOT D,GAUTSCHI O,et al.Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma:An expert consensus[J].Lung Cancer,2015,87(2):89-95.
[13] 李祥芳,田平.临床药师参与抗肿瘤药物治疗与安全管理的实践与研究[J].临床合理用药杂志,2019,12(30):113-114.

临床药师参与肺癌患者靶向治疗的药学服务实践

Clinical pharmacists involved pharmaceutical care practice of targeted therapy for lung cancer patients

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 10

编辑推荐

Metrics

本文评价

[1]	齐泽铖, 李旭, 郭英伟, 徐晓文, 王晓军. TAK1与TCF-4在非小细胞肺癌中表达及其相关性的初步研究[J]. 广州医药, 2023, 54(6): 17-22.
[2]	王合法, 闫光辉, 杨召锋. 非小细胞肺癌化疗患者骨髓抑制发生状况及其影响因素[J]. 广州医药, 2023, 54(2): 61-63.
[3]	卢锐辉, 郑映璇, 张倩雯, 劳淑贞, 赖佩莹. PBL联合SOAP门诊药历提高门诊药师药学服务质量[J]. 广州医药, 2020, 51(1): 100-104.
[4]	肖云华, 李宝秀. 重组人血管内皮抑素联合化疗治疗晚期非小细胞肺癌的效果[J]. 广州医药, 2019, 50(1): 72-75.
[5]	谢建将, 陈敏东, 陈曲海, 陈文广, 梁登峰, 徐子迅, 白文杰. 对比单孔、单操作孔及三孔胸腔镜肺叶切除术治疗早期非小细胞肺癌的临床研究[J]. 广州医药, 2017, 48(5): 32-35.
[6]	赵美玲, 蔡小华, 杨方方, 向琪, 曹小飞. ERCC1、RRM1、TS蛋白表达对晚期非小细胞肺癌个体化治疗的临床观察[J]. 广州医药, 2017, 48(5): 57-60.
[7]	张英燕, 曾建芳, 罗秀玉. 同步放化疗治疗晚期非小细胞肺癌的疗效观察[J]. 广州医药, 2016, 47(3): 26-27.
[8]	田丹, 汪森明, 程越, 王军. 紫杉醇脂质体与紫杉醇联合顺铂治疗晚期非小细胞肺癌的临床研究[J]. 广州医药, 2016, 47(2): 24-26.
[9]	徐舒, 冯高飞, 宋雨鸿. 参一胶囊维持治疗对晚期NSCLC患者炎症因子影响的回顾性研究[J]. 广州医药, 2016, 47(1): 15-17.
[10]	江国杰, 赵菊香, 叶珍珍. 药学服务对门诊中老年COPD患者用药依从性的影响[J]. 广州医药, 2016, 47(1): 41-43.